# Italy Montelukast API Market

> Italy Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 14.81%
- **2024:** $ 25.25 Million
- **2025:** $ 28.99 Million
- **2035:** $ 115.4 Million
- **Key Players:** Merck & Co (US), Teva Pharmaceutical Industries Ltd (IL), Mylan N.V. (US), Cipla Ltd (IN), Aurobindo Pharma (IN), Hikma Pharmaceuticals PLC (GB), Sandoz International GmbH (CH), Zydus Cadila (IN)

**Report ID:** MRFR/HC/51334-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/italy-montelukast-api-market-53095

---

## Market Summary

## **Italy Montelukast API Market Overview**

As per MRFR analysis, the Italy Montelukast API Market Size was estimated at 27 (USD Million) in 2023. The Italy Montelukast API Market Industry is expected to grow from 30.3 (USD Million) in 2024 to 93.86 (USD Million) by 2035. The Italy Montelukast API Market CAGR (growth rate) is expected to be around 10.825% during the forecast period (2025 - 2035).

### **Key Italy Montelukast API Market Trends Highlighted**

The Montelukast API market in Italy is currently characterized by a number of significant trends that are being driven by the increasing demand for asthma and allergy treatment among the population. The demand for Montelukast as a therapeutic option is being driven by the rising prevalence of respiratory disorders in Italy, primarily due to urban pollution and lifestyle factors.

Additionally, healthcare reforms in Italy are promoting the use of generic medications, such as Montelukast, to render them more accessible and affordable for patients. The increasing acceptance of personalized medicine and the increasing interest in innovative drug delivery systems present opportunities for market penetration. Italian pharmaceutical companies are emphasizing the development of controlled-release formulations of Montelukast to meet the unique requirements of individual patients.

Furthermore, it is anticipated that the market potential of Montelukast will be expanded through the discovery of new applications through collaborations between research institutions and industry actors in Italy. Recent developments also suggest a significant increase in the number of digital health initiatives within Italy's healthcare system.

These initiatives have simplified the process of accessing asthma treatments for patients by promoting telemedicine and online consultations. Patients are increasingly turning to remote remedies for their chronic conditions, such as asthma, as a result of the COVID-19 pandemic, which has expedited the digital transformation of healthcare. Therefore, Montelukast is expected to experience an increase in usage due to its efficacy in alleviating respiratory symptoms associated with viral infections.

Additionally, Montelukast's market position could be further solidified by the Italian government's emphasis on public health initiatives and the enhancement of air quality, which could further solidify its relevance in the management of asthma and allergies. In general, the Italy Montelukast API market is characterized by a robust landscape that these trends and the ongoing changes in consumer behavior and health policies have influenced.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **Italy Montelukast API Market Drivers**

### **Increasing Prevalence of Allergic Diseases**

Italy has witnessed a rising trend in allergic diseases, with the Italian Society of Allergy and Clinical Immunology reporting that approximately 20% of the population suffers from some form of allergy. This increased prevalence significantly boosts the demand for Montelukast, a medication frequently prescribed for asthma and allergic rhinitis.

The Italian Ministry of Health has also recognized the need for effective treatments for allergic diseases, leading to enhanced focus and support for Montelukast within the healthcare framework. The increase in allergies is driven partially by urbanization and lifestyle changes, providing a robust market foundation for the Italy Montelukast API Market Industry as healthcare providers look for effective solutions to manage this health crisis.

### **Growing Awareness of Respiratory Conditions**

Public awareness of respiratory conditions has escalated in Italy, especially in the wake of COVID-19, emphasizing the importance of respiratory health. The Italian Ministry of Health reported an increase in respiratory-related consultations and treatments, contributing to a higher demand for effective asthma management solutions. Montelukast, recognized for its efficacy in improving patient outcomes for asthma, is positioned as a key player within the Italy Montelukast API Market Industry.

Furthermore, local health campaigns and initiatives showcase the government's dedication to addressing respiratory issues, promoting the use of medications like Montelukast to enhance patient quality of life.

### **Expansion of the Generic Market**

The patent expiration of Montelukast has led to a surge in generic alternatives, creating a competitive landscape that benefits the Italy Montelukast API Market Industry. Italian pharmaceutical companies, such as Eurogenerics and Mylan, have commenced the production of generic Montelukast formulations, increasing access to this essential medication.

With the generics market projected to grow as affordability and accessibility improve, patients have more treatment options available. According to the Italian Pharmaceutical Association, the generic penetration in the asthma drug market has reached approximately 40%, emphasizing the demand for cost-effective solutions in patient therapy that will continue to bolster the growth of Montelukast production.

## **Italy Montelukast API Market Segment Insights**

### **Montelukast API Market Application Insights**

The Application segment of the Italy **[Montelukast API Market](../../../reports/montelukast-api-market-7886)** is pivotal, reflecting a growing awareness of respiratory and allergic conditions. Asthma continues to be the leading application area due to its widespread prevalence among both adults and children in Italy. The increasing incidence of asthma, influenced by environmental factors such as pollution and allergens, drives the demand for effective treatments.

Similarly, Allergic Rhinitis occupies a significant share within this segment, as approximately one in four individuals in Italy experience the condition, necessitating effective management solutions. The rising cases of Bronchospasm, particularly associated with chronic respiratory diseases, further emphasize the need for Montelukast as a therapeutic agent. Urticaria, although not as dominating, is gaining recognition due to the impact of lifestyle and environmental changes.

This prompts a heightened demand for effective management options. The Others category also plays a crucial role, encompassing various allergic reactions and inflammatory conditions where Montelukast can provide relief. This segment demonstrates strong growth potential as healthcare providers increasingly recognize the versatility and effectiveness of Montelukast in treating multiple conditions.

Overall, the Application segment of the Italy Montelukast API Market is characterized by a diversified approach to addressing the health needs of the population, making it a critical area for ongoing development and research. With the increasing focus on public health initiatives aimed at improving disease management, the Italy Montelukast API Market is set to expand significantly, driven by the rising prevalence of these health conditions and the demand for innovative therapeutic solutions.

Furthermore, this growth is supported by advancements in pharmaceutical formulations and the increasing availability of Montelukast in various dosage forms, enhancing patient adherence and treatment outcomes. The commitment of health authorities in Italy to improve respiratory health further catalyzes the growth of this segment, highlighting the importance of Montelukast in contemporary medical treatment protocols.

As healthcare systems adapt to cater to the needs of a changing demographic landscape, the Application segment remains central to the overall strategy of improving patient care and optimizing health outcomes.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **Italy Montelukast API Market Key Players and Competitive Insights**

The Italy Montelukast API Market is characterized by a robust competitive landscape featuring various players that contribute to the overall growth and dynamics of the sector. Montelukast, known for its efficacy in managing asthma and allergic rhinitis, has seen a surge in demand primarily due to increasing respiratory ailments influenced by environmental factors and lifestyle changes.

This market has become attractive for pharmaceutical companies aiming to establish a strong foothold in the generic segment, which is primarily driven by the need for cost-effective treatment options. Companies operating in this market are focusing on enhancing their production capabilities and acquiring certifications to comply with stringent regulatory standards, thereby establishing themselves as reliable suppliers of Montelukast API not only in Italy but also for export markets across Europe.

Teva Pharmaceutical Industries has emerged as a significant player within the Italy Montelukast API Market, leveraging its extensive experience and global presence to capture a substantial market share. The company is recognized for its commitment to quality and affordability, positioning itself favorably against other competitors. Teva's strength lies in its well-established supply chain network and advanced manufacturing technologies that ensure consistent product quality and efficiency.

Moreover, Teva benefits from a diverse portfolio that includes a range of therapies beyond Montelukast, thereby reducing dependency on a single product and enhancing overall business stability. Their proactive approach to regulatory compliance also showcases Teva's dedication to meeting the evolving demands of the Italian market, further solidifying their presence as a leading API provider.

Intas Pharmaceuticals has made significant strides in the Italy Montelukast API Market by focusing on competitive pricing, high-quality product offerings, and strategic partnerships that enhance their market reach. The company is noted for its robust research and development capabilities, allowing for innovation in product formulations and delivery mechanisms.

Intas has built a commendable reputation tied to its core values of delivering affordable healthcare solutions. Their key products in the API sector include Montelukast among other therapeutic agents, thereby presenting a balanced portfolio that addresses various health issues. In terms of market presence, Intas has expanded through strategic mergers and acquisitions, which have enhanced its production capacity and distribution network within Italy, facilitating a swift response to market demands while maintaining high operational efficiency.

This strategic maneuvering not only strengthens Intas's market position but also showcases its commitment to becoming a key player in the pharmaceutical landscape within Italy.

### **Key Companies in the Italy Montelukast API Market Include**

### **Italy Montelukast API Market Industry Developments**

Recent developments in the Italy Montelukast API Market have been influenced by a number of factors, including increasing demand for asthma and allergy medications. Companies such as Teva Pharmaceutical Industries, Intas Pharmaceuticals, and Torrent Pharmaceuticals have been actively expanding their production capacities to meet the rising demand.

Additionally, Lupin Pharmaceuticals and Glenmark Pharmaceuticals have made advancements in their manufacturing processes to enhance product efficiency. In terms of mergers and acquisitions, in September 2023, Dr. Reddy's Laboratories announced its acquisition of a regional player to strengthen its foothold in the Italy market, which could lead to enhanced innovation in Montelukast API production.

Sun Pharmaceutical Industries and Zydus Cadila continue to explore strategic partnerships aimed at bolstering their market presence within Italy. The Italian government has also implemented favorable regulations to streamline the approval process for therapeutic products, further invigorating the market dynamics. Overall, with the increasing market valuation and aggressive expansions by major players, the Italy Montelukast API Market is experiencing significant growth, reflecting a robust environment for investment and innovation in the pharmaceutical sector.

### **Italy Montelukast API Market Segmentation Insights**

### **Montelukast API Market Application Outlook**

## Market Drivers

### Rising Healthcare Expenditure

Italy's increasing healthcare expenditure is a significant driver for the montelukast api market. The government has allocated substantial resources to enhance healthcare services, with spending projected to reach approximately €200 billion in the coming years. This financial commitment is likely to improve access to essential medications, including montelukast, as healthcare providers are better equipped to offer comprehensive treatment options. The montelukast api market stands to gain from this trend, as higher healthcare budgets may lead to increased prescriptions and a broader patient base seeking effective management for respiratory conditions. As healthcare systems evolve, the demand for montelukast is expected to rise correspondingly.

### Regulatory Framework Enhancements

The regulatory landscape in Italy is evolving, which is positively impacting the montelukast api market. Recent enhancements in regulatory frameworks aim to streamline the approval processes for new medications and generics, thereby facilitating quicker access to essential treatments. The Italian Medicines Agency (AIFA) has implemented measures to expedite the review of applications for montelukast and similar drugs, which may lead to increased availability in the market. This regulatory support is crucial for the montelukast api market, as it encourages pharmaceutical companies to invest in the development and distribution of montelukast, ultimately benefiting patients in need of effective respiratory therapies.

### Advancements in Pharmaceutical Research

Innovations in pharmaceutical research are significantly impacting the montelukast api market in Italy. Ongoing research efforts are focused on enhancing the efficacy and safety profiles of existing medications, including montelukast. The Italian pharmaceutical sector has seen increased investment in research and development, with funding reaching approximately €1 billion in recent years. This investment is likely to foster the development of novel formulations and delivery methods for montelukast, potentially expanding its therapeutic applications. As a result, the montelukast api market may witness a surge in demand as healthcare professionals adopt these advancements to improve patient care and treatment outcomes.

### Growing Awareness of Preventive Healthcare

There is a notable shift towards preventive healthcare in Italy, which is influencing the montelukast api market. Increased public awareness regarding the importance of managing respiratory conditions proactively is leading to higher rates of diagnosis and treatment initiation. Campaigns aimed at educating the population about asthma and allergies have resulted in a greater understanding of the benefits of medications like montelukast. Consequently, the montelukast api market is likely to see an uptick in prescriptions as patients seek to manage their conditions effectively. This trend aligns with the broader healthcare objective of reducing hospital admissions and improving quality of life for individuals with chronic respiratory issues.

### Increasing Prevalence of Allergic Conditions

The montelukast market in Italy is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis. Recent studies indicate that approximately 10% of the Italian population suffers from asthma, with a notable increase in cases among children. This trend is likely to drive demand for effective treatments, including montelukast, which is widely prescribed for managing these conditions. The montelukast api market is thus positioned to benefit from this growing patient population, as healthcare providers seek reliable therapeutic options to address the increasing burden of respiratory diseases. Furthermore, the Italian healthcare system's focus on improving patient outcomes may lead to expanded access to montelukast, further propelling market growth.

## Future Outlook

The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at a 14.81% CAGR from 2025 to 2035, driven by increasing asthma prevalence and rising healthcare expenditure.

**New opportunities:**

- Development of specialized montelukast formulations for pediatric use.
- Expansion into telehealth platforms for remote patient monitoring.
- Strategic partnerships with pharmaceutical companies for co-marketing initiatives.

By 2035, the montelukast API market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing)

In the Italy montelukast api market, the application segment shows a varied distribution of market share among its key categories. Asthma remains the largest segment, capturing a significant share due to the considerable prevalence of this respiratory condition. Allergic Rhinitis follows, with increasing awareness and diagnosis contributing to its market presence. Other applications like Bronchospasm, Urticaria, and Others also constitute relevant portions, albeit smaller than the leading applications.

Growth trends in the application segment are propelled by rising incidence rates of asthma and allergic conditions, coupled with advances in treatment options. The growing prevalence of allergens and environmental pollutants are notable drivers for Allergic Rhinitis, marking it as the fastest-growing application. Innovations in montelukast formulations and increased healthcare access further enhance the treatment landscape, showcasing a dynamic shift in consumer preferences towards effective management of these conditions.

Asthma (Dominant) vs. Urticaria (Emerging)

Asthma is recognized as the dominant application in the Italy montelukast api market, largely due to its critical role in managing chronic respiratory issues in a significant population segment. The established presence of montelukast within this application reflects confidence in its efficacy for asthma management. In contrast, Urticaria is emerging as a relevant segment, driven by increasing cases and a growing awareness of dermatological conditions. While Asthma benefits from historical treatment frameworks and extensive clinical data, Urticaria is rapidly gaining attention with a shift towards recognizing the importance of comprehensive allergy treatment, signaling a marked change in the treatment approaches and emerging opportunities within the market.

## Competitive Benchmarking

The montelukast API market in Italy is characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include the increasing prevalence of asthma and allergic rhinitis, alongside a rising demand for cost-effective therapeutic options. Major players such as Merck & Co (US), Teva Pharmaceutical Industries Ltd (IL), and Mylan N.V. (US) are strategically positioned to leverage their extensive research capabilities and established distribution networks. Merck & Co (US) focuses on innovation through continuous research and development, while Teva Pharmaceutical Industries Ltd (IL) emphasizes regional expansion and partnerships to enhance its market presence. Collectively, these strategies contribute to a competitive environment that is increasingly shaped by innovation and strategic collaborations.
In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of the montelukast API market. The market structure appears moderately fragmented, with several key players exerting influence over pricing and distribution. This fragmentation allows for a variety of competitive strategies, as companies seek to differentiate themselves through quality, reliability, and service.
In October 2025, Teva Pharmaceutical Industries Ltd (IL) announced a strategic partnership with a local Italian pharmaceutical firm to enhance its distribution capabilities within the region. This move is significant as it not only strengthens Teva's market position but also allows for better alignment with local regulatory requirements and consumer preferences. Such partnerships are likely to enhance operational efficiencies and improve market responsiveness.
In September 2025, Mylan N.V. (US) launched a new formulation of montelukast aimed at improving patient compliance. This strategic initiative reflects Mylan's commitment to innovation and addresses the growing demand for more user-friendly medication options. By focusing on patient-centric solutions, Mylan is positioning itself to capture a larger share of the market, particularly among younger demographics who may prioritize convenience.
In August 2025, Merck & Co (US) expanded its manufacturing capabilities in Italy, investing approximately €50 million in a new facility dedicated to the production of montelukast API. This expansion is indicative of Merck's long-term commitment to the Italian market and its strategy to enhance supply chain reliability. By increasing local production, Merck aims to mitigate potential supply disruptions and respond more effectively to market demands.
As of November 2025, current competitive trends in the montelukast API market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the need for collaborative approaches to navigate complex market dynamics. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and robust supply chain management. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge.

## Recent News & Developments

Recent developments in the Italy Montelukast API Market have been influenced by a number of factors, including increasing demand for asthma and allergy medications. Companies such as Teva Pharmaceutical Industries, Intas Pharmaceuticals, and Torrent Pharmaceuticals have been actively expanding their production capacities to meet the rising demand.

Additionally, Lupin Pharmaceuticals and Glenmark Pharmaceuticals have made advancements in their manufacturing processes to enhance product efficiency. In terms of mergers and acquisitions, in September 2023, Dr. Reddy's Laboratories announced its acquisition of a regional player to strengthen its foothold in the Italy market, which could lead to enhanced innovation in Montelukast API production.

Sun Pharmaceutical Industries and Zydus Cadila continue to explore strategic partnerships aimed at bolstering their market presence within Italy. The Italian government has also implemented favorable regulations to streamline the approval process for therapeutic products, further invigorating the market dynamics. Overall, with the increasing market valuation and aggressive expansions by major players, the Italy Montelukast API Market is experiencing significant growth, reflecting a robust environment for investment and innovation in the pharmaceutical sector.

## Report Scope

| MARKET SIZE 2024 | 25.25(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 28.99(USD Million) |
| MARKET SIZE 2035 | 115.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.81% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Teva Pharmaceutical Industries Ltd (IL), Mylan N.V. (US), Cipla Ltd (IN), Aurobindo Pharma (IN), Hikma Pharmaceuticals PLC (GB), Sandoz International GmbH (CH), Zydus Cadila (IN) |
| Segments Covered | Application |
| Key Market Opportunities | Growing demand for montelukast API driven by increasing respiratory disorders and regulatory support for generic formulations. |
| Key Market Dynamics | Regulatory changes and competitive pressures shape the montelukast API market dynamics in Italy. |
| Countries Covered | Italy |

## Frequently Asked Questions

**Q: What was the market valuation of the Italy montelukast API market in 2024?**
A: The market valuation was $25.25 Million in 2024.

**Q: What is the projected market valuation for the Italy montelukast API market in 2035?**
A: The projected valuation for 2035 is $115.4 Million.

**Q: What is the expected CAGR for the Italy montelukast API market during the forecast period 2025 - 2035?**
A: The expected CAGR is 14.81% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the Italy montelukast API market?**
A: Key players include Merck & Co, Teva Pharmaceutical Industries Ltd, Mylan N.V., Cipla Ltd, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Sandoz International GmbH, and Zydus Cadila.

**Q: What are the main application segments of the Italy montelukast API market?**
A: Main application segments include Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, and Others.

**Q: What was the market size for the Asthma segment in 2024?**
A: The market size for the Asthma segment was $10.0 Million to $45.0 Million in 2024.

**Q: How does the market size for Allergic Rhinitis compare to other segments?**
A: The market size for Allergic Rhinitis ranged from $7.0 Million to $30.0 Million, making it one of the larger segments.

**Q: What is the projected growth for the Bronchospasm segment by 2035?**
A: The Bronchospasm segment is expected to grow from $4.0 Million to $20.0 Million by 2035.

**Q: What is the valuation range for the Urticaria segment in 2024?**
A: The valuation range for the Urticaria segment was $2.0 Million to $10.0 Million in 2024.

**Q: What does the future hold for the Others segment in the Italy montelukast API market?**
A: The Others segment is projected to grow from $2.25 Million to $10.4 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/italy-montelukast-api-market-53095*